# ELI LILLY & Co (LLY)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/eli-lilly-and-co/ JSON: https://steadybase.io/company/eli-lilly-and-co.json Checked Nov 10, 2026. Latest filing read: Oct 29, 2026.

## Company

- Legal name: ELI LILLY & Co
- Ticker: LLY (NYSE)
- SEC CIK: 0000059478
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Indianapolis, IN
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: lilly.com
- Investor relations: https://investor.lilly.com/
- LinkedIn: https://www.linkedin.com/company/eli-lilly-and-company
- Next earnings date: Feb 3, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $65.2B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.html
- Net income: $20.6B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.html
- SG&A: $11.1B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.html
- Employees: 50,000 as of Feb 12, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.html
- Shares outstanding: 940,745,031 as of Oct 26, 2026 (10-Q filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.html
- Auditor: Ernst & Young LLP, Indianapolis, Indiana, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm

## Business

Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Net income | SG&A |
|---|---|---|---|
| Dec 31, 2025 | $65.2B | $20.6B | $11.1B |
| Dec 31, 2024 | $45.0B | $10.6B | $8.6B |
| Dec 31, 2023 | $34.1B | $5.2B | $7.4B |
| Dec 31, 2022 | $28.5B | $6.2B | $6.4B |
| Dec 31, 2021 | $28.3B | $5.6B | $6.4B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/eli-lilly-and-co.json

## Officers and directors

- David A. Ricks, Lilly chair and CEO. Source: 8-K filed Oct 29, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000104/q326lillysalesandearningsp.htm
- David Ricks, Chair, President, and Chief Executive Officer (CEO). Source: 10-K filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- Lucas Montarce, EVP & CFO. LinkedIn: https://linkedin.com/in/lucas-montarce. Source: Form 4 filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/59478/000175244726000004/0001752447-26-000004-index.htm
- Melissa Seymour, EVP, Global Quality. LinkedIn: https://linkedin.com/in/melissa-seymour-mba-54ba226. Source: Form 4 filed Sep 11, 2026, https://www.sec.gov/Archives/edgar/data/59478/000203208926000004/0002032089-26-000004-index.htm
- Adrienne S. Brown, EVP, President LLY Imm. Source: 3/A filed Sep 4, 2026, https://www.sec.gov/Archives/edgar/data/59478/000209688826000006/0002096888-26-000006-index.htm
- Edgardo Hernandez, EVP & Pres., Mfg. Operations. LinkedIn: https://linkedin.com/in/edgardo-hernandez-2435351ab. Source: Form 4 filed Sep 4, 2026, https://www.sec.gov/Archives/edgar/data/59478/000186105226000006/0001861052-26-000006-index.htm
- Eric Dozier, EVP, Chief People Officer. LinkedIn: https://linkedin.com/in/eric-dozier. Source: Form 4 filed Sep 4, 2026, https://www.sec.gov/Archives/edgar/data/59478/000195597226000008/0001955972-26-000008-index.htm
- Patrik Jonsson, EVP & President, LLY Int'l. LinkedIn: https://linkedin.com/in/patrik-jonsson-05597761. Source: Form 4 filed Aug 18, 2026, https://www.sec.gov/Archives/edgar/data/59478/000178605426000006/0001786054-26-000006-index.htm
- Anat Hakim, EVP, GC & Secretary. LinkedIn: https://linkedin.com/in/anat-hakim-b7272233. Source: Form 4 filed Aug 10, 2026, https://www.sec.gov/Archives/edgar/data/59478/000168555626000006/0001685556-26-000006-index.htm
- Ilya Yuffa, EVP&Pres, LLY USA&Global Capab. LinkedIn: https://linkedin.com/in/ilya-yuffa. Source: Form 4 filed Jun 11, 2026, https://www.sec.gov/Archives/edgar/data/59478/000182600126000006/0001826001-26-000006-index.htm
- Kenneth L. Custer, EVP & President, Card Met Hlth. LinkedIn: https://linkedin.com/in/kennethcuster. Source: Form 4 filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/59478/000207154226000004/0002071542-26-000004-index.htm
- Adrienne Brown, Executive Vice President and President, Lilly Immunology. Source: 10-K filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- Carole Ho, Executive Vice President and President, Lilly Neuroscience. LinkedIn: https://linkedin.com/in/carolehoneuro. Source: 10-K filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- Daniel Skovronsky, M.D., Ph.D., Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Laboratories. Source: 10-K filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- Diogo Rau, EVP & CIDO. LinkedIn: https://linkedin.com/in/diogo-rau-811217. Source: 4/A filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000186025326000006/0001860253-26-000006-index.htm
- Donald Zakrowski, Senior Vice President, Finance, and Chief Accounting Officer. LinkedIn: https://linkedin.com/in/donald-zakrowski-39a3b5a. Source: 10-K filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- Jacob Van Naarden, Executive Vice President, President, Lilly Oncology and Head of Corporate Business Development. LinkedIn: https://linkedin.com/in/jacob-van-naarden-b610541. Source: 10-K filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- Kenneth Custer, Ph.D., Executive Vice President and President, Lilly Cardiometabolic Health. Source: 10-K filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- Daniel Skovronsky, EVP, CS&PO & Pres. LRL. LinkedIn: https://linkedin.com/in/danielskovronsky. Source: Form 4 filed Feb 11, 2026, https://www.sec.gov/Archives/edgar/data/59478/000174147426000004/0001741474-26-000004-index.htm
- Naarden Jacob Van, EVP,Pres LLY Oncology&HdCorpBD. Source: Form 4 filed Feb 11, 2026, https://www.sec.gov/Archives/edgar/data/59478/000166125426000004/0001661254-26-000004-index.htm
- Donald A. Zakrowski, SVP, Finance, & CAO. Source: Form 4 filed Aug 11, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000083/0000059478-26-000083-index.htm
- CAROLYN BERTOZZI, Ph.D., Director. Source: 10-K filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- ERIK FYRWALD, Director. Source: 10-K filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- GABRIELLE SULZBERGER, Director. Source: 10-K filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- JAMERE JACKSON, Director. Source: 10-K filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm

## Recent 8-K events

- Oct 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000104/lly-20261029.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/lly-20260805.htm
- May 20, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312526232707/d148580d8k.htm
- May 7, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000048/lly-20260504.htm
- Apr 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/lly-20260430.htm
- Feb 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000008/lly-20260204.htm
- Nov 21, 2025: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000271/lly-20251118.htm
- Oct 30, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000251/lly-20251030.htm
- Aug 20, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312525184093/d929636d8k.htm
- Aug 7, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000202/lly-20250807.htm

## Insider trades (Form 4)

- Nov 2, 2026: Anat Hakim (EVP, GC & Secretary) sold 5,000 shares, about $7.0M. Source: https://www.sec.gov/Archives/edgar/data/59478/000168555626000008/0001685556-26-000008-index.htm
- Aug 17, 2026: Patrik Jonsson (EVP & President, LLY Int'l) sold 6,500 shares, about $7.6M. Source: https://www.sec.gov/Archives/edgar/data/59478/000178605426000006/0001786054-26-000006-index.htm
- Aug 10, 2026: Donald A. Zakrowski (SVP, Finance, & CAO) sold 2,000 shares, about $2.4M. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000083/0000059478-26-000083-index.htm
- Aug 7, 2026: Anat Hakim (EVP, GC & Secretary) sold 5,000 shares, about $6.0M. Source: https://www.sec.gov/Archives/edgar/data/59478/000168555626000006/0001685556-26-000006-index.htm
- Jun 10, 2026: Ilya Yuffa (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares, about $2.9M. Source: https://www.sec.gov/Archives/edgar/data/59478/000182600126000006/0001826001-26-000006-index.htm
- Nov 13, 2025: Donald A. Zakrowski (SVP, Finance, & CAO) sold 1,000 shares, about $1.0M. Source: https://www.sec.gov/Archives/edgar/data/59478/000156153925000006/0001561539-25-000006-index.htm
- Aug 28, 2025: Donald A. Zakrowski (SVP, Finance, & CAO) sold 1,000 shares, about $734,930. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000234/0000059478-25-000234-index.htm
- Aug 15, 2025: Lucas Montarce (EVP & CFO) bought 715 shares, about $494,630. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000222/0000059478-25-000222-index.htm
- Aug 13, 2025: Ralph Alvarez (Director) bought 758 shares, about $500,470. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000220/0000059478-25-000220-index.htm
- Aug 13, 2025: Naarden Jacob Van (EVP & Pres., Lilly Oncology) bought 1,000 shares, about $647,360. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000218/0000059478-25-000218-index.htm
- Aug 12, 2025: David A. Ricks (President, Chair, and CEO) bought 1,632 shares, about $1.1M. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000216/0000059478-25-000216-index.htm
- Aug 12, 2025: Daniel Skovronsky (EVP, CSO & Pres. LRL & LLY Imm) bought 1,000 shares, about $634,410. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000214/0000059478-25-000214-index.htm
- Aug 12, 2025: Gabrielle Sulzberger (Director) bought 117 shares, about $75,018. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000212/0000059478-25-000212-index.htm
- Aug 12, 2025: J. Erik Fyrwald (Director) bought 1,565 shares, about $1.0M. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000210/0000059478-25-000210-index.htm
- Aug 11, 2025: Ilya Yuffa (EVP&Pres, LLY USA&Global Capab) sold 1,250 shares, about $783,763. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000208/0000059478-25-000208-index.htm

## What management said

- "Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook" David A. Ricks, Lilly chair and CEO (8-K filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000104/q326lillysalesandearningsp.htm

## Latest filings

- 8-K filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/59478/000005947826000104/lly-20261029.htm
- 10-K filed Feb 12, 2026: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- 10-Q filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/lly-20260930.htm
- DEF 14A filed Mar 20, 2026: https://www.sec.gov/Archives/edgar/data/59478/000005947826000029/lly-20260317.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/